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regulated gene located at 3q23, is regulated by
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Background: Treatment of advanced stage ovarian cancer continues to be challenging due to acquired drug
resistance and lack of early stage biomarkers. Genes identified to be aberrantly expressed at the 3q26.2 locus
(i.e. SnoN/SkiL) have been implicated in ovarian cancer pathophysiology. We have previously shown that SnoN
expression is increased in advanced stage ovarian cancers and alters cellular response to arsenic trioxide (As2O3).
Findings: We now demonstrate increased DNA copy number levels (TCGA data) of phospholipid scramblase 1
(PLSCR1, located at 3q23) whose transcript expression in ovarian cell lines is highly correlated with SnoN mRNA.
Interestingly, SnoN can modulate PLSCR1 mRNA levels in the absence/presence of interferon (IFN-2α). Both IFN-2α
and As2O3 treatment can modulate PLSCR1 mRNA levels in ovarian carcinoma cells. However, SnoN siRNA does not
lead to altered PLSCR1 protein implicating other events needed to modulate its protein levels. In addition, we
report that PLSCR1 can modulate aspects of the As2O3 cellular response.
Conclusions: Our findings warrant further investigation into the role of PLSCR1 in ovarian cancer development
and chemoresistance.
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Ovarian cancerFindings
Epithelial ovarian cancer represents the most common
gynecological cancer in women with an unfortunate high
mortality rate due to acquired chemotherapeutic resist-
ance [1]. Our earlier published studies indicate that the
3q26.2 chromosomal region is highly amplified in ovar-
ian cancers [2] and harbors various oncogenes including
EVI1 [2], PKCι [3], and SnoN/SkiL [4]. In particular, we
previously demonstrated that SnoN, a negative tran-
scriptional regulator of TGFβ signaling, modulates the
pro-survival autophagic pathway in response to arsenic
trioxide (As2O3), a chemotherapeutic agent used in the
treatment of acute promyelocytic leukemia (APL) [5].
Interestingly, there are reports which indicate that genes
located at and proximal to the 3q26 locus may regulate
each other. For instance, both EVI1 and PIK3CA can* Correspondence: mnanjund@usf.edu
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distribution, and reproduction in any mediumregulate SnoN expression [6,7]. Herein, we now report that
the expression of phospholipid scramblase 1 (PLSCR1), lo-
cated at 3q23, can be modulated via SnoN. PLSCR1 has
been implicated in maintaining plasma membrane lipid
asymmetry, regulating growth factor signaling pathways, in
modulating tumor growth in mouse xenograft models [8],
and cancer development [9,10]. The role of PLSCR1 in
ovarian cancer and in modulating response to chemothera-
peutic agents has yet to be fully understood.
Our previous aCGH studies from 235 ovarian cancer pa-
tient samples demonstrated that SnoN was increased at
the DNA copy number level [4]. We now identify through
Oncomine bioinformatic analyses (ovarian TCGA dataset
(https://tcga-data.nci.nih.gov.tcga/) that the DNA copy
number levels of PLSCR1 in addition to SnoN are
altered similarly (Figure 1A). Furthermore, using
cBioportal [11], we identified that SnoN is amplified in
31% of the cases whereas PLSCR1 is amplified in 13%
of the cases (70 out of 570 samples amplified both
genes). To determine whether SnoN and PLSCR1 genestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 (See legend on next page.)
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Figure 1 Concordance between SnoN and PLSCR1 RNA expression in ovarian cancer cell lines. (A) Oncomine analysis of the Ovarian TCGA
data set shows increased copy number of PLSCR1 (left panel) and SnoN (right panel) in ovarian serous cystadenocarcinomas (582 specimens) in
contrast to normal ovary (127 specimens). (B) Correlation analysis between PLSCR1 and SnoN copy number in ovarian cancer specimens. (C) RNA
was harvested from normal (T80 and T29) and malignant (OVCAR8, OVCA429, HEY, and SKOV3) ovarian cell lines. PLSCR1 mRNA levels were
quantified by quantitative PCR. The results are displayed as relative RNA-fold change. Results are representative of duplicate experiments. (D)
Correlation analyses between PLSCR1 and SnoN RNA and DNA copy number in ovarian cancer cell lines. (E) Western blotting was performed
using antibodies against the proteins indicated using cell lysates isolated from the cell lines described in (C). Results are representative of
duplicate experiments. (F) Correlation analyses between PLSCR1 and SnoN protein expression.
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copy number variation (CNV) estimates (Additional
file 1: Methods and Materials) for SnoN and PLSCR1
genes in R (http://www.R-project.org/) (Figure 1B). In
ovarian cancers with PLSCR1 amplification, SnoN is
gained. When SnoN is amplified, PLSCR1 is only gained
in ~33% of the samples (R2 = 0.2474) (Figure 1B). We next
evaluated the RNA and protein levels of PLSCR1 in vari-
ous normal and malignant ovarian cell lines via real-time
PCR and western analysis. Similar to SnoN, PLSCR1 ex-
pression was low in normal immortalized T80 ovarian
cells and highly expressed in the ovarian cancer cell lines
(Figure 1C and E). Although PLSCR1 and SnoN expres-
sion were highly correlated (via linear regression) at the
RNA level (Figure 1D), there was a discordance at the
protein level (Figure 1F) which has been reported
previously for other genes [12,13]. Furthermore, the
DNA copy number of PLSCR1 and SnoN is nearly al-
ways the same in ovarian cancer cell lines (R2 = 0.6411)
(Additional file 2: Table S1). Collectively, these results
demonstrate that, PLSCR1 is increased at the DNA and
RNA levels in ovarian cancers and cell lines in com-
parison to normal cells, similar to SnoN, and can be
co-amplified in a certain proportion of ovarian cancer
specimens. However, there likely exist additional levels
of regulation which contribute to modulating PLSCR1
protein levels.
Since PLSCR1 is located in close proximity to SnoN at
the 3q locus [2], we next assessed whether SnoN could
modulate PLSCR1 expression. To address this question,
we reduced SnoN expression via siRNA in HEY ovarian
carcinoma cells (cell line used previously to investigate
role of SnoN [5] and PLSCR1 [8]); this was followed by
quantitation of PLSCR1 mRNA levels via real-time PCR.
Upon SnoN knockdown (~88% and 95% at RNA and
protein level, respectively), we observed a significant re-
duction (~35%) in PLSCR1 mRNA (Figure 2A) implicating
SnoN in the regulation of PLSCR1 transcription. These re-
sults were validated by utilizing the PLSCR1 promoter
upon SnoN knockdown in T80 cells (Figure 2B) or
with TGFβ (50 pM) (Figure 2C); both conditions led to
a marked reduction in PLSCR1 promoter activity
suggesting that activation of the TGFβ signaling cas-
cade downregulates PLSCR1 expression. PLSCR1mRNA levels were also down-regulated following 24 h
TGFβ treatment (Figure 2D, left panel). SnoN mRNA
has been previously shown to increase 1–3 hours post-
TGFβ treatment [4] (Figure 2D, right panel) implicat-
ing discordance between SnoN and PLSCR1 mRNA
levels with TGFβ. Intriguingly, overexpression of both
the wild type and C/A PLSCR1 mutant (which localizes
to the nuclear compartment [14]) in T80 cells led to a
marked induction of plasminogen activator inhibitor-1
(PAI-1) expression (Figure 2E); these results suggest
that PLSCR1 could modulate TGFβ cellular responses,
similar to SnoN [4].
Since PLSCR1 is an interferon (IFN)-inducible gene
[15,16], we next determined whether SnoN could, in
part, modulate PLSCR1 expression upon IFN-2α treat-
ment. Supporting previous reports, treatment of HEY cells
with IFN-2α (3000 IU/ml) led to a dramatic increase
in PLSCR1 protein from 6 up to 24 hours (Figure 3A,
3.7-fold) and RNA (Figure 3B, 2.9-fold). Similar results
were also observed in a series of IFN-resistant and sen-
sitive pancreatic cancer cell lines (Additional file 3:
Figure S1, A-F). Strikingly, SnoN protein was induced
(in the absence of SnoN mRNA changes (Additional
file 4: Figure S2, A)) at 3 h post-IFN treatment; changes in
SnoN occurred prior to those observed in PLSCR1. These
results implicate SnoN in the transcriptional regulation of
PLSCR1 expression upon IFN treatment. In addition, we
noted that the induced PLSCR1 localized predominantly
at the plasma membrane in HEY cells (Figure 3C and D),
assessed via immunofluorescence and subcellular fraction-
ation (with a very minor fraction localizing to the nuclear
compartment). Since chemotherapeutic agents can gener-
ate intracellular reactive oxygen species (ROS) which
modulates expression levels of various proteins [5], we
next assessed whether the changes we observed in
PLSCR1 and SnoN expression with IFN were due to ROS.
Thus, we co-treated HEY cells with N-acetyl-L-cysteine
(NAC), an anti-oxidant free radical scavenger, together
with IFN for 9 h. However, there were no marked changes
in PLSCR1 and SnoN protein levels in the presence of
NAC (Additional file 4: Figure S2, B); these results suggest
that the IFN-induced changes in SnoN and PLSCR1 may
be independent of ROS. Strikingly, knockdown of SnoN
levels (via siRNA) in HEY cells in the presence of IFN-2α
***
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Figure 2 Knockdown of SnoN Reduces PLSCR1 mRNA Levels. (A) RNA was isolated from HEY cells 48-hours post-transfection with SnoN
siRNA. PLSCR1 (left panel) and SnoN (right panel) mRNA levels were quantified by real-time PCR. Results are representative of duplicate
experiments. (B) T80 cells were transfected with the PLSCR1 promoter followed by either SnoN knockdown (B) or 24 h TGFβ treatment (C). Cell
lysates were harvested and luciferase activity was quantified. Results are representative of duplicate experiments. (D) RNA was isolated from T80
cells treated with TGFβ (3 and 18 h). PLSCR1 (left panel) and SnoN (right panel) mRNA levels were quantified by real-time PCR. Results are
representative of duplicate experiments. (E) T80 cells were mock transfected or transiently transfected with either wild type PLSCR1 (WT-PLSCR1,
0.25 μg to 2.0 μg) or C/A PLSCR1 mutant (C/A-PLSCR1, 0.25 μg to 2.0 μg). Cell lysates were analyzed by western blotting for the proteins
indicated. Results are representative of duplicate experiments.
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but also PLSCR1 RNA (Figure 3E and F, 1.8-fold). How-
ever, changes in PLSCR1 protein were again not detected
with IFN-treatment following SnoN siRNA (Additional
file 4: Figure S2, C); we propose that this could be due to
the long half-life of PLSCR1 protein (assessed utilizingcycloheximide (CHX), an inhibitor of protein translation
(results not shown)) or additional mechanisms needed
to contribute with SnoN to modulate PLSCR1 protein.
We have previously demonstrated the role of As2O3 as
an effective chemotherapeutic agent inducing cell death
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Figure 3 SnoN modulates IFN-2α-mediated induction of PLSCR1 mRNA. (A) HEY cells were treated with 3000 IU/ml IFN-2α (15 min – 24 h).
Cell lysates were harvested followed by western blotting for the indicated proteins. Results are representative of triplicate experiments. (B) HEY
cells were treated with 3000 IU/ml IFN-2α (0, 1, and 3 hours). RNA was isolated followed by real-time PCR analysis to quantify PLSCR1 mRNA
levels. Results are representative of duplicate experiments. HEY cells were treated with 3000 IU/ml IFN-2α (18 h) followed by immunofluorescence
staining (C) or subcellular fractionation of cytoplasmic and nuclear fractions (D) which were analyzed by western blotting for the proteins
indicated. Results are representative of duplicate experiments. (E) HEY cells were transfected with non-targeting or SnoN siRNA followed by
IFN-2α treatment (3 h). Forty-eight hours post-transfection, total RNA was isolated followed by quantitation of PLSCR1 (E) and SnoN (F) mRNA by
real-time PCR. Results are representative of duplicate experiments.
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http://www.molecular-cancer.com/content/12/1/32mediated by SnoN induction [5]. We first assessed
whether PLSCR1 protein is altered upon As2O3 treat-
ment in ovarian cancer cells. In this regard, we treated
HEY cells with 25 μM As2O3 (0 – 24 h). In contrast
to SnoN (increasing between 6 – 24 h), we noted a
marked reduction in PLSCR1 protein (~75% reduction)
(Figure 4A and B). We next determined whether this re-
duction in PLSCR1 protein was due to proteasomal deg-
radation via the use of MG132 (proteasome inhibitor).
Co-treatment of HEY cells with 5 and 25 μM As2O3 for
6 h and 18 h with 5 μM MG132 did not lead to a signifi-
cant recovery in PLSCR1 levels; these results suggest amechanism of PLSCR1 protein regulation independent
of the proteasome (Figure 4C). Indeed, As2O3 also alters
PLSCR1 RNA levels which might together reflect
As2O3-induced transcriptional regulation of PLSCR1
(Figure 4D). In order to determine whether PLSCR1 plays
a role in modulating As2O3–induced cell death response
in ovarian cancer cells, we reduced PLSCR1 expression via
siRNA. Upon knockdown of PLSCR1 in the presence of
As2O3, we observed a marked increase in the levels of
caspase-3 activity (results not shown) as well as cleaved
PARP ((7.9-fold) a marker of apoptosis, Figure 4E) con-
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Figure 4 PLSCR1 modulates As2O3-induced cell death response in HEY ovarian carcinoma cells. (A) HEY cells were treated with 25 μM
As2O3 (15 min - 24 h) followed by harvesting of cell lysates and analyses via western blotting for the indicated proteins. Results are representative
of triplicate experiments. (B) Densitometric analysis of PLSCR1 protein levels of data presented in (A). (C) HEY cells were treated with 25 μM As2O3
(6 or 18 h) in the absence or presence of MG132 (5 μM) followed by harvesting of cell lysates and analyses via western blotting for the indicated
proteins. Results are representative of duplicate experiments. (D) HEY cells were treated with 25 μM As2O3 (6 or 18 h). RNA was isolated and
analyzed for PLSCR1 mRNA levels by real-time PCR. Results are representative of duplicate experiments. (E) Cell lysates were collected from HEY
cells treated with non-targeting or PLSCR1 siRNA in the absence or presence of 25 μM As2O3 (18 h). Western blotting was performed for the
proteins indicated. Results are representative of triplicate experiments. (F) Cells were transfected with pEGFP-LC3. Twenty-four hours post
transfection, cells were treated with non-targeting and PLSCR1 siRNA followed by treatment with 10 μM As2O3. Immunofluorescence was
performed (left panel) and the data was quantitated (bar graphs, right panel) by counting the number of cells positive for EGFP-LC3 punctae.
Results are representative of duplicate experiments. (G) A schematic showing regulation of PLSCR1 mRNA by SnoN and As2O3 (and its effect on
the cell death response) in HEY cells. In addition to the downstream effect of overexpressed PLSCR1 on PAI-1, a TGFβ target gene, in T80 cells.
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http://www.molecular-cancer.com/content/12/1/32autophagy, Figure 4E) validated by GFP-LC3 autophagy
assays ((~20%), Figure 4F). Similar to SnoN [5], these re-
sults suggest that PLSCR1 may contribute to the As2O3-
induced apoptotic and autophagic response.
In the current study, we demonstrate that PLSCR1 and
SnoN DNA copy number as well as their RNA levels are
correlated. By modulating SnoN expression, PLSCR1mRNA levels appear to be co-regulated (Figure 4G). Of
interest, SnoN knockdown does not alter PLSCR1 protein
possibly suggesting that other mediators are involved in its
regulation. Nonetheless, similar to SnoN, reduction in
PLSCR1 levels appears to increase the cellular sensitivity
to As2O3. Whether PLSCR1 modulates sensitivity to
carboplatin/paclitaxel or whether the effects of As2O3 and
Kodigepalli et al. Molecular Cancer 2013, 12:32 Page 7 of 7
http://www.molecular-cancer.com/content/12/1/32TGFβ are mediated via IFN remain to be investigated.
Thus, further investigations are warranted to delve into
the significance of these findings in ovarian cancer deve-
lopment and chemoresistance.
Additional files
Additional file 1: Materials and Methods.
Additional file 2: Table S1. DNA Copy Number Variation in PLSCR1
and SnoN across multiple ovarian cancer cell lines. Forty-seven ovarian
cancer cell lines were assessed for CNV in PLSCR1 and SnoN. There does
not appear to be significant copy number changes for both genes in the
cell lines presented where the copy number is nearly invariable from the
normal copy number.
Additional file 3: Figure S1. Induction of PLSCR1 protein expression in
response to IFN-2α in a series of resistant and sensitive pancreatic cancer
cell lines. (A) IFN-2α treatment of AsPC-1 cells and PANC-1 cells. (B) IFN-
2α treatment of BxPC-3 cells and MIA PaCa-2 cells. Cell lysates were
harvested from cell lines described in (A) and (B) followed by western
analyses for the indicated antibodies. (C) Cell lysates were harvested from
IFN-2α treated MIA PaCa-2 cells followed by western analyses for the
indicated antibodies. (D) RNA was isolated from IFN-2α treated MIA PaCa-
2 cells followed by real-time PCR analyses to quantify PLSCR1 mRNA
levels. (E) and (F) Growth assays were performed in AsPC-1, PANC-1,
BxPC-3, and MIA PaCa-2 cells in response to IFN-2α treatment.
Additional file 4: Figure S2. No effect on PLSCR1 protein levels upon
NAC treatment or SnoN knockdown in the absence/presence of IFN-2α.
(A) HEY cells were treated with 3000 IU/ml IFN-2α (0, 1, 3 hours). RNA
was isolated followed by real-time PCR analysis to quantify SnoN mRNA
levels. (B) HEY cells were treated with IFN-2α, NAC, or IFN-2α in
combination with NAC at the specified doses. Cell lysates were harvested
and analyzed by western blotting analyses for the indicated antibodies.
(C) HEY cells were transfected with SnoN siRNA and treated with/without
IFN-2α. Cell lysates were harvested and western analyses performed for
the indicated antibodies.
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